Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jardiance's Label Expansion Will Change Diabetes Management

Executive Summary

US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.

You may also be interested in...



Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim

The latest drug development news and highlights from our FDA Performance Tracker.

Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim

Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.

India’s Trial Approval Timelines Report Card – Some Red Lines?

India’s streamlined clinical trial approvals process appears to have made some gains, but top industry experts tell Pink Sheet how the non-standardized approach of Subject Expert Committees is a “major handicap” for applicants.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel